logo

Last Update

This profile was last updated on 8/1/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Martin Schlumberger?

Martin J. Schlumberger

Professor of Oncology

University of Paris-Sud

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

University of Paris-Sud

Background Information

Employment History

Primary Investigator and Professor of Oncology

Institut Gustave Roussy


World Congress on Thyroid Cancer


Endocrinologist

ThyCa Inc


Affiliations

Thyroid Cancer Alliance

Board Member


Education

M.D.


M.D.

University of Paris - Sud


Web References(41 Total References)


About TCA - Thyroid Cancer Alliance

thyroidcanceralliance.org [cached]

Martin Schlumberger, MD, PhD
Professor of Oncology University of Paris-Sud


Authors - Thyroid Disease ManagerThyroid Disease Manager

www.thyroidmanager.org [cached]

Martin Schlumberger , MD
Professor of Oncology, University of Paris-Sud, Director, Nuclear Medicine and Endocrine Tumors Division, Institut Gustave-Roussy, Villejuif, Paris, France.


Authors - Thyroid Disease ManagerThyroid Disease Manager

www.thyroidmanager.org [cached]

Martin Schlumberger , MD
Professor of Oncology, University of Paris-Sud, Director, Nuclear Medicine and Endocrine Tumors Division, Institut Gustave-Roussy, Villejuif, Paris, France.


thyroidcanceralliance.org

Martin Schlumberger, MD, PhD
Professor of Oncology University of Paris-Sud


Anti-VEGF agent lenvatinib significantly improves progression-free survival in thyroid cancer patients | The Angiogenesis Foundation

www.angio.org [cached]

"We are confident that, based on our findings, lenvatinib will eventually become a standard treatment for radioiodine-resistant thyroid cancer," said study lead author Dr. Martin Schlumberger, a professor of oncology at the University Paris Sud in Paris, France.
"As little as a year ago, this group of patients had no effective treatment options. It's remarkable that we now have two active drugs in this setting, both of them tyrosine kinase inhibitors," he added in a statement provided by the American Society of Clinical Oncology. Side effects such as high blood pressure, diarrhea, decreased appetite, decreased weight and nausea, caused physicians to lower doses in almost 80 percent of patients, although Schlumberger said the smaller doses didn't disrupt the drug's effect.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory